FIELD: pharmacology.
SUBSTANCE: ophthalmic composition for ocular hypertension treatment comprises at least one therapeutically active agent in a concentration of 0.01 to 0.12% (w/v), at least one tonicity agent, glycerin or mannitol, a solubilizer-polysorbate 80 and a preservative- benzalkonium chloride. The therapeutically active agent has the structure where X1 and X2 independently represent CH2, O or S, and R1 is H or C1-C6 alkyl.
EFFECT: application of a group of inventions allows to increase the efficiency of ocular hypertension treatment due to a novel combination of ingredients of the composition where the active agent solubility is increased.
19 cl, 8 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
IMPROVED BIMATOPROST OPHTHALMIC SOLUTION | 2006 |
|
RU2363471C2 |
BIMATOPROST AND THYMOLOL SOLUTIONS NOT CONTAINING CONSERVANTS | 2011 |
|
RU2624534C2 |
COMPOSITIONS AND METHODS USED FOR DECREASING OCULAR HYPERTENSION | 1998 |
|
RU2197970C2 |
OCULAR COMPOSITIONS FOR DRUG-DELIVERY TO POSTERIOR SEGMENT OF THE EYE | 2014 |
|
RU2665953C2 |
OPHTHALMIC FORMULATIONS FOR DRUG DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE | 2014 |
|
RU2768489C2 |
OPHTHALMIC COMPOSITIONS CONTAINING PROSTAMIDE RELEASING NITROGEN OXIDE | 2019 |
|
RU2781022C2 |
PHARMACEUTICAL COMPOSITIONS POSSESSING DESIRABLE BIOAVAILABILITY | 2009 |
|
RU2503453C2 |
PHARMACEUTICAL PREPARATIVE FORMS OF LATRUNCULIN | 2007 |
|
RU2434633C2 |
PHARMACEUTICAL COMPOSITION OF TAFLUPROST | 2021 |
|
RU2761625C2 |
ANDROGEN COMPOSITION FOR TREATING OPHTHALMIC CONDITIONS | 2012 |
|
RU2599036C2 |
Authors
Dates
2017-09-11—Published
2010-11-05—Filed